Volume 51, Issue 5, Pages (May 2007)

Slides:



Advertisements
Similar presentations
Judith Bosschieter, André N. Vis, Henk G. van der Poel, Luc M
Advertisements

The PSA Era is not Over for Prostate Cancer
Volume 70, Issue 6, Pages (December 2016)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 70, Issue 1, Pages (July 2016)
Testosterone Therapy in Men With Prostate Cancer
Volume 66, Issue 6, Pages (December 2014)
Volume 63, Issue 5, Pages (May 2013)
Determination of vhl Gene Mutations in Sporadic Renal Cell Carcinoma
Volume 61, Issue 5, Pages (May 2012)
Combination of Alfuzosin and Sildenafil is Superior to Monotherapy in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction  Steven A. Kaplan,
Volume 53, Issue 5, Pages (May 2008)
Volume 64, Issue 4, Pages (October 2013)
Volume 50, Issue 5, Pages (November 2006)
Volume 71, Issue 4, Pages (April 2017)
Volume 53, Issue 5, Pages (May 2008)
Let the Games Begin (with EAU Approval)
Ashish M. Kamat, Sima Porten  European Urology 
Meric Sengoz, Ufuk Abacioglu, İlknur Cetin, Levent Turkeri 
Prostate Cancer Epidemic in Sight?
Volume 72, Issue 5, Pages (November 2017)
Volume 56, Issue 1, Pages (July 2009)
The Global Risk of Bladder Cancer: Let's Just Do Something About It!
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Back to the Future: Introduction and Conclusions
Volume 61, Issue 5, Pages (May 2012)
Volume 53, Issue 4, Pages (April 2008)
Prostate Cancer Detection: A View of the Future
Volume 59, Issue 6, Pages (June 2011)
P.M.J. Moonen, L.A.L.M. Kiemeney, J.A. Witjes  European Urology 
Volume 63, Issue 5, Pages (May 2013)
Volume 64, Issue 4, Pages (October 2013)
Volume 69, Issue 3, Pages (March 2016)
Volume 70, Issue 1, Pages (July 2016)
Volume 64, Issue 3, Pages (September 2013)
Volume 57, Issue 4, Pages e41-e42 (April 2010)
Volume 52, Issue 4, Pages (October 2007)
Prostate Cancer Epidemic in Sight?
James N. Armitage, Stuart O. Irving, Neil A. Burgess  European Urology 
Volume 59, Issue 1, Pages (January 2011)
The PSA Era is not Over for Prostate Cancer
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 66, Issue 6, Pages (December 2014)
Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review  Sven van.
Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia
Volume 65, Issue 6, Pages (June 2014)
Volume 70, Issue 6, Pages (December 2016)
The Economic Costs of Overactive Bladder in Germany
Karl-Dietrich Sievert, Bastian Amend, Arnulf Stenzl  European Urology 
Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels
Volume 73, Issue 2, Pages (February 2018)
TERT Promoter Mutations Occur Frequently in Urothelial Papilloma and Papillary Urothelial Neoplasm of Low Malignant Potential  Liang Cheng, Rodolfo Montironi,
Volume 50, Issue 5, Pages (November 2006)
CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System
Testicular Cancer Variations in Time and Space in Europe
Volume 53, Issue 1, Pages (January 2008)
Volume 54, Issue 6, Pages (December 2008)
Volume 53, Issue 5, Pages (May 2008)
Prognostic Impact of Comorbidity in Patients with Bladder Cancer
European Urology is “Your” Journal
Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg 
Molecular Classification of Non–Muscle-Invasive Bladder Cancer (pTa Low-Grade, pT1 Low-Grade, and pT1 High-Grade Subgroups) Using Methylation of Tumor-Suppressor.
Multiplexed Methylation Profiles of Tumor Suppressor Genes in Bladder Cancer  Maria José Cabello, Laura Grau, Noreli Franco, Esteban Orenes, Miguel Alvarez,
Economic Burden of Bladder Cancer Across the European Union
Volume 53, Issue 6, Pages (June 2008)
Volume 53, Issue 2, Pages (February 2008)
Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer  Sten Holmäng  European Urology.
Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas 
Volume 54, Issue 1, Pages (July 2008)
Volume 51, Issue 5, Pages (May 2007)
Presentation transcript:

Volume 51, Issue 5, Pages 1267-1274 (May 2007) Urinary CYFRA 21.1 Is Not a Useful Marker for the Detection of Recurrences in the Follow-Up of Superficial Bladder Cancer  Jesus Fernandez-Gomez, Juan J. Rodríguez-Martínez, Safwan Escaf Barmadah, Jorge García Rodríguez, Dra. Maite Allende, Antonio Jalon, Roberto Gonzalez, Miguel Álvarez-Múgica  European Urology  Volume 51, Issue 5, Pages 1267-1274 (May 2007) DOI: 10.1016/j.eururo.2006.12.019 Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 1 Receiver operator characteristic curves analysis in our series with a calculated area under the curve of 0.58. CYFRA cutoffs: 1.5ng/ml (S: 0.696; 1-S: 0.572), 4ng/ml (S: 0.43; 1-S: 0.311), and 5.4ng/ml (S: 0.4; 1-S: 0.25). European Urology 2007 51, 1267-1274DOI: (10.1016/j.eururo.2006.12.019) Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 2 Receiver operator characteristic curves analysis in our series excluding cases with benign conditions occurring within 3 mo before CYFRA 21.1 determination and patients treated with brachytherapy or external beam radiation (area under the curve of 0.66). CYFRA cutoffs: 1.5ng/ml (S: 0.696; 1-S: 0.458), 4ng/ml (S: 0.43; 1-S: 0.193) and 5.4ng/ml (S: 0.4; 1-S: 0.137). European Urology 2007 51, 1267-1274DOI: (10.1016/j.eururo.2006.12.019) Copyright © 2006 European Association of Urology Terms and Conditions